Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 11:18 PM
Ignite Modification Date: 2025-12-25 @ 8:57 PM
NCT ID: NCT00953056
Description: One participant in the Cohort III-RotaTeq™ treatment group received RotaTeq™ at the first and third dose but placebo at the second dose in error. The participant had moderate or mild diarrhea after the second and third doses, respectively. The participant's AE data is included in the AE tables under the Cohort III-RotaTeq™ treatment group.
Frequency Threshold: 5
Time Frame: None
Study: NCT00953056
Study Brief: A Study of V260 in Healthy Chinese Adults, Children and Infants (V260-028)(COMPLETED)
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Cohort I - RotaTeq™, Adults Adults randomized to receive a single dose of RotaTeq™. None None 0 24 6 24 View
Cohort I - Placebo, Adults Adults randomized to receive a single dose of matching placebo to RotaTeq™. None None 0 24 2 24 View
Cohort II - RotaTeq™, Children Children randomized to receive a single dose of RotaTeq™. None None 0 24 6 24 View
Cohort II - Placebo, Children Children randomized to receive a single dose of matching placebo to RotaTeq™. None None 0 24 3 24 View
Cohort III - RotaTeq™, Infants Infants randomized to receive 3 doses of RotaTeq™. None None 0 24 18 24 View
Cohort III - Placebo, Infants Infants randomized to receive 3 doses of matching placebo to RotaTeq™. None None 3 24 14 24 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
DIARRHOEA SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA 12.1 View
BRONCHOPNEUMONIA SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA 12.1 View
ENCEPHALITIS VIRAL SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA 12.1 View
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
DIARRHOEA SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA 12.1 View
VOMITING SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA 12.1 View
MALAISE SYSTEMATIC_ASSESSMENT General disorders MedDRA 12.1 View
PYREXIA SYSTEMATIC_ASSESSMENT General disorders MedDRA 12.1 View
NASOPHARYNGITIS SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA 12.1 View
HEADACHE SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA 12.1 View
COUGH SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA 12.1 View